KALA

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Kala Pharmaceuticals Inc

NASDAQ | KALA

1.38

USD

(

0.00%

)

At Close (As of Jan 1, 1970)

$9.90M

Market Cap

-

P/E Ratio

-5.96

EPS

$20.60

52 Week High

$1.10

52 Week Low

HEALTHCARE

Sector

KALA Chart

Recent Chart
Price Action

KALA Technicals

Tags:

KALA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$259K
Total Revenue $0
Cost Of Revenue $259K
Costof Goods And Services Sold $259K
Operating Income -$41M
Selling General And Administrative $18M
Research And Development $22M
Operating Expenses $40M
Investment Income Net -
Net Interest Income -$3.7M
Interest Income $2.1M
Interest Expense $5.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.3M
Income Before Tax -$39M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$39M
Comprehensive Income Net Of Tax -
Ebit -$44M
Ebitda -$41M
Net Income -$39M

Revenue & Profitability

Earnings Performance

KALA Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $55M
Total Current Assets $53M
Cash And Cash Equivalents At Carrying Value $51M
Cash And Short Term Investments $51M
Inventory -
Current Net Receivables -
Total Non Current Assets $2.7M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $1.6M
Other Non Current Assets -
Total Liabilities $43M
Total Current Liabilities $17M
Current Accounts Payable $628K
Deferred Revenue -
Current Debt -
Short Term Debt $11M
Total Non Current Liabilities $26M
Capital Lease Obligations $1.8M
Long Term Debt $20M
Current Long Term Debt $10M
Long Term Debt Noncurrent -
Short Long Term Debt Total $32M
Other Current Liabilities $5M
Other Non Current Liabilities $4.7M
Total Shareholder Equity $12M
Treasury Stock -
Retained Earnings -$668M
Common Stock $6K
Common Stock Shares Outstanding $5.5M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$29M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $259K
Capital Expenditures $208K
Change In Receivables -
Change In Inventory $0
Profit Loss -
Cashflow From Investment -$208K
Cashflow From Financing $30M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$39M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$259K
Total Revenue $0
Cost Of Revenue $259K
Costof Goods And Services Sold $259K
Operating Income -$41M
Selling General And Administrative $18M
Research And Development $22M
Operating Expenses $40M
Investment Income Net -
Net Interest Income -$3.7M
Interest Income $2.1M
Interest Expense $5.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.3M
Income Before Tax -$39M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$39M
Comprehensive Income Net Of Tax -
Ebit -$44M
Ebitda -$41M
Net Income -$39M

KALA Profile

Kala Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Kala Pharmaceuticals Inc, based in Watertown, Massachusetts, is a forward-thinking biopharmaceutical company focused on the discovery, development, and commercialization of cutting-edge therapies for ocular conditions. Leveraging its proprietary nanoparticle-based mucus penetrating particle (MPP) technology, Kala aims to significantly enhance drug delivery and therapeutic effectiveness in ophthalmic care. By prioritizing innovative solutions for eye diseases, the company is strategically positioned to address critical unmet medical needs in the ophthalmology market, solidifying its role as a leader in the biopharmaceutical landscape.

VHAI
-20.00%
$0.00
VIVK
-1.72%
$0.28
YYAI
-10.71%
$0.12
BURU
+1.09%
$0.34
RXRX
-6.33%
$6.36
EPWK
+26.46%
$0.09
NAYA
+85.67%
$1.40
IVF
+85.67%
$1.40
BITF
-18.39%
$5.28
CGBS
-39.47%
$0.03
PLUG
-9.61%
$3.48
NVDA
+1.10%
$181.81
YDKG
-49.73%
$0.09
ADAP
+6.02%
$0.19
BYND
-22.39%
$0.52
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.52%
$3.09
NIO
+0.14%
$6.83
BBD
+1.87%
$3.26
MIRA
+36.36%
$1.80
SCNX
-17.63%
$0.58
F
-0.17%
$11.74
AADI
+24.28%
$2.61
FEMY
+35.37%
$0.74
KVUE
-13.22%
$14.11
ACHR
-8.90%
$11.87
INTC
-0.83%
$36.84
TLRY
-8.33%
$1.54
HPE
-10.14%
$22.50
TSLA
-1.47%
$428.75
IONZ
+19.44%
$3.44
SOFI
-5.10%
$26.60
CAN
-14.79%
$1.67
AMD
-1.69%
$234.56
ONDS
-13.77%
$8.19
DFLI
-32.48%
$1.33
AXDX
-61.36%
$0.03
ETHD
+6.47%
$3.78
RIG
-2.41%
$3.23
AAL
-4.88%
$11.89
MARA
-11.27%
$20.26
CLF
-2.79%
$13.56
GDXD
-10.23%
$0.60
BTG
+4.76%
$5.94
LAES
-15.08%
$6.36
AMC
-2.48%
$2.75
BTBT
-9.11%
$3.69
GNPX
-43.39%
$0.47
RF
-5.61%
$23.35
QBTS
-9.64%
$40.46
QS
-13.38%
$15.46
RR
-7.95%
$5.67
VSEE
-13.85%
$0.51
NAK
-15.15%
$2.24
LGCB
+19.39%
$1.97
GPUS
-5.78%
$0.36
ABAT
-36.64%
$5.67
RGTZ
+29.08%
$11.23
HBAN
-5.18%
$15.37
SNAP
-1.89%
$7.76
QSI
-3.42%
$2.54
QUBT
-11.72%
$18.73
BAC
-3.51%
$50.44
CIFR
-10.98%
$18.72
WOK
+1.55%
$0.05
UUUU
-13.20%
$21.69
CRML
-14.52%
$19.42
CLSK
-13.83%
$19.98
ASST
-6.24%
$0.90
IREN
-9.04%
$61.83
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
KEY
-5.35%
$16.78
PLTR
-0.83%
$178.12
T
+0.49%
$26.20
SOUN
-2.99%
$20.76
MU
+5.51%
$202.53
AMZN
-0.51%
$214.47
JBLU
-3.63%
$4.76
SMR
-10.83%
$47.64
APLD
-2.96%
$36.64
FNB
-7.21%
$14.65
WTO
-88.87%
$0.13
GRAB
-3.54%
$5.71
RMBL
+60.50%
$3.21
AAPL
-0.75%
$247.45
WULF
-10.40%
$13.86
NOK
+0.53%
$5.68
ADD
-25.47%
$0.05
HIMS
-5.75%
$59.15
AUUD
+0.97%
$2.06
SOND
+79.34%
$1.65
JOBY
-8.69%
$16.07
CRWV
+1.79%
$141.74
TOVX
-48.67%
$0.43
SLNH
-2.33%
$4.19
IONQ
-9.41%
$65.59
SRM
+53.27%
$10.30
SATL
-29.71%
$2.91
VHAI
-20.00%
$0.00
VIVK
-1.72%
$0.28
YYAI
-10.71%
$0.12
BURU
+1.09%
$0.34
RXRX
-6.33%
$6.36
EPWK
+26.46%
$0.09
NAYA
+85.67%
$1.40
IVF
+85.67%
$1.40
BITF
-18.39%
$5.28
CGBS
-39.47%
$0.03
PLUG
-9.61%
$3.48
NVDA
+1.10%
$181.81
YDKG
-49.73%
$0.09
ADAP
+6.02%
$0.19
BYND
-22.39%
$0.52
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.52%
$3.09
NIO
+0.14%
$6.83
BBD
+1.87%
$3.26
MIRA
+36.36%
$1.80
SCNX
-17.63%
$0.58
F
-0.17%
$11.74
AADI
+24.28%
$2.61
FEMY
+35.37%
$0.74
KVUE
-13.22%
$14.11
ACHR
-8.90%
$11.87
INTC
-0.83%
$36.84
TLRY
-8.33%
$1.54
HPE
-10.14%
$22.50
TSLA
-1.47%
$428.75
IONZ
+19.44%
$3.44
SOFI
-5.10%
$26.60
CAN
-14.79%
$1.67
AMD
-1.69%
$234.56
ONDS
-13.77%
$8.19
DFLI
-32.48%
$1.33
AXDX
-61.36%
$0.03
ETHD
+6.47%
$3.78
RIG
-2.41%
$3.23
AAL
-4.88%
$11.89
MARA
-11.27%
$20.26
CLF
-2.79%
$13.56
GDXD
-10.23%
$0.60
BTG
+4.76%
$5.94
LAES
-15.08%
$6.36
AMC
-2.48%
$2.75
BTBT
-9.11%
$3.69
GNPX
-43.39%
$0.47
RF
-5.61%
$23.35
QBTS
-9.64%
$40.46
QS
-13.38%
$15.46
RR
-7.95%
$5.67
VSEE
-13.85%
$0.51
NAK
-15.15%
$2.24
LGCB
+19.39%
$1.97
GPUS
-5.78%
$0.36
ABAT
-36.64%
$5.67
RGTZ
+29.08%
$11.23
HBAN
-5.18%
$15.37
SNAP
-1.89%
$7.76
QSI
-3.42%
$2.54
QUBT
-11.72%
$18.73
BAC
-3.51%
$50.44
CIFR
-10.98%
$18.72
WOK
+1.55%
$0.05
UUUU
-13.20%
$21.69
CRML
-14.52%
$19.42
CLSK
-13.83%
$19.98
ASST
-6.24%
$0.90
IREN
-9.04%
$61.83
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
KEY
-5.35%
$16.78
PLTR
-0.83%
$178.12
T
+0.49%
$26.20
SOUN
-2.99%
$20.76
MU
+5.51%
$202.53
AMZN
-0.51%
$214.47
JBLU
-3.63%
$4.76
SMR
-10.83%
$47.64
APLD
-2.96%
$36.64
FNB
-7.21%
$14.65
WTO
-88.87%
$0.13
GRAB
-3.54%
$5.71
RMBL
+60.50%
$3.21
AAPL
-0.75%
$247.45
WULF
-10.40%
$13.86
NOK
+0.53%
$5.68
ADD
-25.47%
$0.05
HIMS
-5.75%
$59.15
AUUD
+0.97%
$2.06
SOND
+79.34%
$1.65
JOBY
-8.69%
$16.07
CRWV
+1.79%
$141.74
TOVX
-48.67%
$0.43
SLNH
-2.33%
$4.19
IONQ
-9.41%
$65.59
SRM
+53.27%
$10.30
SATL
-29.71%
$2.91
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.